Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.56
-0.15 (-1.95%)
Jun 30, 2026, 1:21 PM EDT - Market open
Entrada Therapeutics Revenue
Entrada Therapeutics had revenue of $875.00K in the quarter ending March 31, 2026, a decrease of -95.74%. This brings the company's revenue in the last twelve months to $5.74M, down -96.67% year-over-year. In the year 2025, Entrada Therapeutics had annual revenue of $25.42M, down -87.94%.
Revenue (ttm)
$5.74M
Revenue Growth
-96.67%
P/S Ratio
48.42
Revenue / Employee
$37,750
Employees
152
Market Cap
272.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 25.42M | -185.36M | -87.94% |
| Dec 31, 2024 | 210.78M | 81.77M | 63.38% |
| Dec 31, 2023 | 129.01M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Niagen Bioscience | 130.42M |
| Bicycle Therapeutics | 63.50M |
| Invivyd | 55.87M |
| Orchestra BioMed Holdings | 32.72M |
| Foghorn Therapeutics | 28.22M |
| Adagene | 7.67M |
| Fate Therapeutics | 6.32M |
| AC Immune | 4.62M |
TRDA News
- 20 days ago - Entrada Therapeutics Transcript: AGM 2026 - Transcripts
- 22 days ago - Entrada Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 22 days ago - Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim - TheFly
- 22 days ago - Entrada Therapeutics Slides: Corporate presentation - Filings
- 26 days ago - Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Entrada Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts